The US FDA's efforts to use a risk-based Current Good Manufacturing Practices (cGMP) surveillance inspection model for drug manufacturers is expected to bring about an uptick in the agency's inspections and their frequency in the Asia Pacific region.
written on 02.04.2014
FDA foreign inspections to rise amid "inventory" build up
